SuperworthOnKure Therapeutics EPS OKUR
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$3.50
- Latest quarter, Q2 FY26
- −$0.31
- Fiscal year 2025
- −$4.41
OnKure Therapeutics' earnings per share was −$3.50 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.31.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.41 | n/a |
| FY2023 | −$25.18 | n/a |
| FY2022 | −$21.10 | n/a |
| FY2021 | −$48.60 | n/a |
| FY2020 | −$95.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.31 | n/a | −$3.50 | |
| Q1 FY26 | −$1.11 | n/a | −$4.33 | |
| Q4 FY25 | −$0.99 | n/a | −$4.41 | |
| Q3 FY25 | −$1.09 | n/a | n/a | |
| Q2 FY25 | −$1.14 | n/a | n/a | |
| Q1 FY25 | −$1.19 | n/a | n/a | |
| Q3 FY24 | −$36.55 | n/a | −$118.74 | |
| Q2 FY24 | −$44.82 | n/a | −$87.87 | |
| Q1 FY24 | −$30.37 | n/a | −$49.55 | |
| Q4 FY23 | −$7.00 | n/a | −$25.18 | |
| Q3 FY23 | −$5.68 | n/a | −$23.68 | |
| Q2 FY23 | −$6.50 | n/a | −$23.30 |
Against its peers
Companies in Drug Manufacturers - General nearest OnKure Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| OKUROnKure Therapeutics | −$3.50 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on OnKure Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.